Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncogene

• Publication date

  2006-06-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1209379PMID 16462768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic targeting of the tumor microenvironment.

  2005cited by this paper
• Tumor-stroma interactions.

  2005cited by this paper
• Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.

  2005cited by this paper
• BRAFE600-associated senescence-like cell cycle arrest of human naevi

  2005cited by this paper
• The role of B-RAF in melanoma

  2005cited by this paper
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.

  2004influential reference
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004influential reference
• Guilty as charged: B-RAF is a human oncogene.

  2004influential reference
• Effect Of Human Natural Killer and γδ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice

  2004cited by this paper
• Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".

  2004cited by this paper
• High Sensitivity Scanning of Colorectal Tumors and Matched Plasma DNA for Mutations in APC, TP53, K‐RAS, and BRAF Genes with a Novel DHPLC Fluorescence Detection Platform

  2004cited by this paper
• BRAF kinase gene V599E mutation in growing melanocytic lesions.

  2004cited by this paper
• Microarray expression profiling in melanoma reveals a BRAF mutation signature

  2004cited by this paper
• Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.

  2004cited by this paper
• Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.

  2004cited by this paper
• BRAF alterations are associated with complex mutational profiles in malignant melanoma

  2004cited by this paper
• Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.

  2003cited by this paper
• Remodeling of the Microenvironment by Aggressive Melanoma Tumor Cells

  2003cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Raf proteins and cancer: B-Raf is identified as a mutational target.

  2003cited by this paper
• A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion1

  2002influential reference
• Mutations of the BRAF gene in human cancer

  2002influential reference
• Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases.

  2002cited by this paper
• N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin.

  1998cited by this paper
• N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma

  1994cited by this paper
• Ras mutations in human melanoma: a marker of malignant progression.

  1994cited by this paper

• Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line

  2025cites this paper
• Papillary Craniopharyngioma: an integrative and comprehensive review.

  2024cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches

  2024cites this paper
• Hypocrellin: A Natural Photosensitizer and Nano‐Formulation for Enhanced Molecular Targeting of PDT of Melanoma

  2024cites this paper
• Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

  2024cites this paper
• Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors

  2024cites this paper
• Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance

  2023cites this paper
• Mefloquine induces ER stress and apoptosis in BRAFi‐resistant A375‐BRAFV600E/NRASQ61K malignant melanoma cells targeting intracranial tumors in a bioluminescent murine model

  2022cites this paper
• Heterogeneity in Melanoma

  2022cites this paper
• Dissection of molecular and histological subtypes of papillary thyroid cancer using alternative splicing profiles

  2022cites this paper
• A B‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies

  2022cites this paper
• Clinical associations and genetic interactions of oncogenic BRAF alleles

  2022cites this paper
• Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients

  2022cites this paper
• Tumor Biology and Natural History

  2021cites this paper
• Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities

  2021cites this paper
• The origins and genetic interactions of KRAS mutations are allele- and tissue-specific

  2021cites this paper
• Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

  2021cites this paper
• YY1 is a potential key player in the pathogenesis of malignant melanoma

  2021cites this paper
• BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells

  2021cites this paper
• Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma

  2021cites this paper
• Novel insights into the pathogenesis and treatment of NRAS mutant melanoma

  2021cites this paper
• Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond

  2021cites this paper
• Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors

  2021cites this paper
• IER2-induced senescence drives melanoma invasion through osteopontin

  2021cites this paper
• Vemurafenib drives EMT gene expression in BRAFi-resistant BRAFV600E/NRASQ61K melanoma enhancing tumor growth and metastasis in a bioluminescent murine model.

  2021cites this paper
• Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors

  2021cites this paper
• Melanoma Metabolism: Cell Survival and Resistance to Therapy.

  2020cites this paper
• Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling

  2020cites this paper
• Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors.

  2020cites this paper
• The Association of Residential Altitude on the Molecular Profile and Survival of Melanoma: Results of an Interreg Study

  2020cites this paper
• The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

  2020cites this paper
• Oncogenetic Network Estimation with Disjunctive Bayesian Networks

  2020cites this paper
• Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

  2020cites this paper
• Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort

  2020cites this paper
• TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.

  2020cites this paper
• Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance

  2020cites this paper
• T-Type Calcium Channels: A Potential Novel Target in Melanoma

  2020cites this paper
• Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma

  2020cites this paper
• Cancer Stem Cell Challenges in Melanoma Characterization and Treatment

  2019cites this paper
• Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability

  2019cites this paper
• Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

  2019cites this paper
• CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features

  2019cites this paper
• A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

  2019cites this paper
• Targeting the ERK Signaling Pathway in Melanoma

  2019cites this paper
• Pairwise tests for conditional selection use evolutionary logic to predict intrinsic drug resistance in ALK alterations

  2019cites this paper
• BRAF-Mutant Melanoma

  2019cites this paper
• Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation

  2019cites this paper
• Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• Does the gene matter? Genotype–phenotype and genotype–outcome associations in congenital melanocytic naevi[Link]

  2019cites this paper
• Rôle de la nanobiomécanique dans la formation de métastases cérébrales et la sclérose latérale amyotrophique

  2018cites this paper
• Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells

  2018cites this paper
• Progress in melanoma modelling in vitro

  2018cites this paper
• Developing statistical and bioinformatic analysis of genomic data from tumours

  2018cites this paper
• Role of nano-biomechanics in brain metastasis formation and amyotrophic lateral sclerosis

  2018cites this paper
• KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations

  2018cites this paper
• CaDrA: A computational framework for performing candidate driver analyses using binary genomic features

  2017cites this paper
• Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

  2017cites this paper
• Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.

  2017cites this paper
• Intratumor and Intertumor Heterogeneity in Melanoma

  2017cites this paper
• What makes oncogenes mutually exclusive?

  2017cites this paper
• Metastatic pathways in patients with cutaneous melanoma

  2017cites this paper
• Hyperactivation of extracellular signal-regulated kinase (ERK) by RAS-mediated signaling or inhibition of dual specificity phosphatase 6 (DUSP6) is associated with toxicity in lung adenocarcinoma cells with mutations in KRAS or EGFR

  2017cites this paper
• Cancer Clonal Evolution and Intra-tumor Heterogeneity

  2017cites this paper
• Novel ultra-sensitive digital PCR assays for screening and detection of rare missense mutations in (proto)-oncogenes

  2017cites this paper
• Identification of KIT as a Suppressor of BRAFV600E-Mutant Melanoma

  2017cites this paper
• Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags

  2016cites this paper
• NFATc2 is an intrinsic regulator of melanoma dedifferentiation

  2016cites this paper
• Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

  2016cites this paper
• Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

  2016cites this paper
• NRASQ61R immunohistochemistry: a new tool for mutational status screening in challenging melanoma samples

  2016cites this paper
• Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay.

  2016cites this paper
• Phytochemicals for the Management of Melanoma.

  2016cites this paper
• BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells

  2016cites this paper
• Heterogeneity in Melanoma.

  2016cites this paper
• BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer

  2016cites this paper
• New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.

  2016cites this paper
• NRAS mutant melanoma: an overview for the clinician for melanoma management.

  2016cites this paper
• Benign thyroid nodules with RAS mutation grow faster

  2016cites this paper
• The impact of sequencing on diagnosis and treatment of malignant melanoma

  2016cites this paper
• Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas

  2016cites this paper
• Sema 6 A and Mical 1 control cell growth and survival of BRAFV 600 E human melanoma cells

  2015cites this paper
• Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

  2015cites this paper
• Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

  2015cites this paper
• Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

  2015cites this paper
• Mutational Heterogeneity in Melanoma: An Inconvenient Truth.

  2015cites this paper
• Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

  2015influential citation
• NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

  2015cites this paper
• Mutational status of naevus‐associated melanomas

  2015cites this paper
• Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment.

  2015cites this paper
• Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

  2015cites this paper
• Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.

  2015cites this paper
• Circulating tumor cells as biomarkers in cancer

  2015cites this paper
• DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.

  2014cites this paper
• Molecular pathology of cutaneous melanoma.

  2014cites this paper
• Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

  2014cites this paper
• Concomitant BRAFV600E Mutation and RET/PTC Rearrangement Is a Frequent Occurrence in Papillary Thyroid Carcinoma

  2014cites this paper
• Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles

  2014cites this paper
• Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types

  2014cites this paper